Table 3.

Univariate analysis for overall survival and progression free survival.

Characteristics	OS		PFS
	Hazard Ratio (95% CI)	p-Value	Hazard Ratio (95% CI)	p-Value
Age ≥ 70	0.833 (0.568 to 1.191)	0.302	1.044 (0.759 to 1.449)	0.7716
Gender	1.140 (0.797 to 1.653)	0.4571	1.174 (0.874 to 1.618)	0.2705
Tumor burden	0.545 (0.369 to 0.749)	0.0004	0.635 (0.448 to 0.817)	0.0011
Lymphnodes	1.173 (0.833 to 1.691)	0.3413	1.215 (0.919 to 1.673)	0.1585
Liver	0.546 (0.293 to 0.727)	0.0009	0.728 (0.458 to 1.005)	0.0535
Bone	0.575 (0.334 to 0.774)	0.0016	0.679 (0.436 to 0.892)	0.0098
Brain	0.431 (0.168 to 0.507)	<0.0001	0.593 (0.307 to 0.796)	0.0038
Other met sites	1.476 (1.022 to 2.140)	0.0375	1.518 (1.131 to 2.113)	0.0063
N of metastatic sites > 2	0.818 (0.312 to 1.999)	0.6198	1.303 (0.609 to 2.746)	0.5025
Diagnosis(NSCLC vs. other)	2.277 (1.254 to 3.143)	0.0034	2.093 (1.320 to 2.822)	0.0007
ECOG PS ≥ 1	0.281 (0.170 to 0.356)	<0.0001	0.446 (0.275 to 0.518)	<0.0001
Line (I vs. II or more)	0.566 (0.398 to 0.831)	0.0032	0.632 (0.459 to 0.854)	0.0031

Eastern Cooperative Oncology Group (ECOG) performance status (PS); OS: overall survival; PFS: progression free survival.